| Nov 6 |
Novo Nordisk: A GLP-1 Leader Faces Increasing Competition
|
| Nov 5 |
2024 election results, Fed meeting, earnings: What to Watch
|
| Nov 5 |
Novo Nordisk Earnings Are Soon. It’s All About Weight-Loss Drug Sales.
|
| Nov 5 |
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
|
| Nov 5 |
Is Novo Nordisk A/S (NVO) The Best European Stock To Buy According to Hedge Funds?
|
| Nov 5 |
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
|
| Nov 5 |
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
|
| Nov 5 |
Novo Nordisk Q3 2024 Earnings Preview
|
| Nov 5 |
Hims & Hers will start selling a generic weight loss drug
|
| Nov 5 |
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology
|
